Impaired neurodevelopment in preterm infants is caused by prematurity itself; however, hypoxia/ ischemia, inflammation, and hyperoxia contribute to the extent of impairment. Because preterm birth is accompanied by a dramatic decrease in 17b-estradiol (E2) and progesterone, preliminary clinical studies have been carried out to substitute these steroids in preterm infants; however, they failed to confirm significantly improved neurologic outcomes. We therefore hypothesized that the persistently high postnatal production of fetal zone steroids [mainly dehydroepiandrosterone (DHEA)] until term could interfere with E2-mediated protection. We investigated whether E2 could reduce hyperoxia-mediated apoptosis in three immature glial cell types and detected the involved receptors. Thereafter, we investigated protection by the fetal zone steroids DHEA, 16a-hydroxy-DHEA, and androstenediol. For DHEA, the involved receptors were evaluated. We examined aromatases, which convert fetal zone steroids into more estrogenic compounds. Finally, cotreatment was compared against single hormone treatment to investigate synergism. In all cell types, E2 and fetal zone steroids resulted in significant dose-dependent protection, whereas the mediating receptors differed. The neuroprotection by fetal zone steroids highly depended on the cell type-specific expression of aromatases, the receptor repertoire, and the potency of the fetal zone steroids toward these receptors. No synergism in fetal zone steroid and E2 cotreatment was detected in two of three cell types. Therefore, E2 supplementation may not be beneficial with respect to neuroprotection because fetal zone steroids circulate in persistently high concentrations until term in preterm infants. Hence, a refined experimental model for preterm infants is required to investigate potential treatments. (Endocrinology 158: 1419(Endocrinology 158: -1435(Endocrinology 158: , 2017 P reterm infants are more vulnerable to central nervous system injury because of their immaturity compared with term neonates. Additional factors, such as the intrinsic vulnerability of immature oligodendrocytes, cerebral hypoxia/ischemia, oxygen, and systemic infection/ inflammation, contribute to the extent of injury (1, 2). Consequences are cognitive, attentional, behavioral, and socialization deficits that heavily affect the quality of life for approximately 25%-50% of preterm survivors (3, 4).
the central nervous system in preterm infants are therefore white matter injuries, such as periventricular leukomalacia (6) . Periventricular leukomalacia consists of a focal and a diffuse component; the focal component is caused by localized necrosis of all cell types, and the diffuse component is a cell-specific lesion caused by an acute loss of early differentiating oligodendrocytes (2) . Infection and ischemia are considered key pathogenic factors, and observational data have also implicated hyperoxia in the pathogenesis of the diffuse component (1, 7) . In utero, the fetal arterial oxygen partial pressure is maintained at low levels of ,30 mm Hg (8) , but the arterial oxygen tension increases to 65 to 80 mm Hg in preterm infants after birth (9) . Furthermore, oxygen supplementation is used in neonatal intensive care in resuscitation and treatment of neonatal lung disease. Plasma concentrations of antioxidant enzymes and glutathione are significantly lower in preterm infants compared with term infants (10, 11) . Therefore, the immature brain has a markedly lower antioxidant capacity, and immature stages of oligodendrocytes show a particular susceptibility to oxidative stress (12, 13) . For example, 48-hour exposure to 80% O 2 results in cell death, decreased proliferation and delayed maturation of oligodendrocyte precursor cells (OPCs), followed by hypomyelination of the white matter in a rodent model of neonatal hyperoxia (14, 15) . Applying this model, 17b-estradiol (E2) reduces oxygen-induced apoptotic cell death (12) .
The fetal zone is a specialized compartment of the fetal adrenal cortex in humans and higher primates. It produces steroid hormones that regulate maturation and intrauterine homeostasis (16, 17) . The main precursor from the fetal zone is dehydroepiandrosterone sulfate (DHEAS), which is produced in increasing amounts of up to 100 to 200 mg per day until term (18, 19) . DHEAS is used by the placenta for biosynthesis of different estrogens (20) , which has led to the term "feto-placental unit" (21) . Because the placenta lacks the cytochrome P450 enzyme CYP17, de novo estrogen synthesis depends on these steroid hormones from fetal and maternal adrenal glands (22) .
Preterm birth disrupts the feto-placental unit, and synthesis of estrogens is no longer possible. The result is a 100-fold drop in plasma estrogen levels in the preterm infant compared with intrauterine levels (23, 24) . The fetal zone shrinks rapidly in term infants, whereas the fetal zone of preterm infants produces persistently high quantities of DHEAS until the time of the termed birth (25, 26) .
This dramatic drop in estrogen and progesterone plasma levels after preterm birth has led to the idea of replacement therapy to mimic intrauterine conditions to potentially improve the premature infant's regular development and to protect the immature brain in case of neurologic complications (27) . Trotter and colleagues (24, 28) investigated this hypothesis after numerous promising studies of neuroprotection with E2 and progesterone in adult experimental models (29, 30) . In their study, 83 premature infants were randomly assigned to supplementation with E2 and progesterone to maintain intrauterine concentrations. At the time the infants were discharged home, no effects on survival or vulnerability for intracerebral hemorrhage could be detected (28) . Five years later, no significant differences between the replacement and placebo groups were found in the Gross Motor Function Classification Scale or in the presence of paresis, cerebral palsy, or spasticity (31) .
To investigate the discrepancy between experimental models and findings of clinical studies, the mechanism of E2-mediated protection needs to be elucidated. When neuroprotective effects of E2 in the preterm model were reported previously, the mechanism of protection was rarely investigated. In general, the action of E2 can be mediated via the two classical estrogen receptors (ERs)-ER-a and ER-b-as well as via the nonclassical G protein-coupled estrogen receptor (GPER). The GPER initiates its effects through nongenomic pathways, whereas the classical ERs initiate effects through genomic and nongenomic pathways (32) (33) (34) . Subsequently, initiated nongenomic effects also modulate gene expression (35) (36) (37) . All types of ER are expressed in a region-specific (38) (39) (40) and sex-specific (41) (42) (43) manner in the brain.
Because fetal zone steroids are precursors for placental estrogen synthesis, they are structurally related to estrogens and thus can interact with ERs (44) . For example, dehydroepiandrosterone (DHEA) and DHEAS and its metabolites, 5-androsten-3b, 17b-diol [androstenediol (Adiol)], and 5-androsten-3b, 16a-diol-17-one [16a-hydroxy-DHEA (16OH-DHEA)], activate ER-a and/or ER-b (45) (46) (47) . Additionally, intracellular aromatases (CYP19) can convert DHEA and its metabolites into more estrogenic molecules that exert an even stronger effect on ERs.
In case of conjugated DHEA, 16OH-DHEA, and Adiol, concentrations in the micromolar range have been measured in the fetal umbilical arterial and venous blood at preterm birth (48) . Previous work by our group showed persistently high urinary excretion rates of fetal zone steroids in preterm infants in contrast to term infants (26) . As a result, fetal zone steroids create a unique hormonal milieu in preterm infants, which might lead to continuous activation of both classical ERs. Therefore, we recently published the hypothesis that the continuous activation of both classical ERs in preterm infants might explain why supplementing E2 showed no significant improvement in the neurologic outcome in previous preliminary studies (20) .
To test this hypothesis, we chose three different immature glial cell types to take potential cell typespecific outcomes into account: (a) mice-derived primary OPCs, (b) the rat-derived immature oligodendroglial cell line OLN-93, and (c) the rat-derived immature astroglial cell line C6. First, we investigated the vulnerability of the different cell types to hyperoxiamediated cell death, as well as the underlying type of cell death. Thereafter, we tested whether E2 could reduce cell death and detected the involved receptors. Afterward, we investigated the protective effects of DHEA, Adiol, and 16OH-DHEA under the same conditions. In the case of DHEA, the involved receptors were further evaluated. By using an inhibitor of intracellular aromatases, we examined how much influence the conversion of fetal zone steroids into more estrogenic compounds has on protection. Finally, cotreatment experiments were compared against single hormone treatments to investigate potential synergistic effects.
Materials and Methods

Cell culture conditions
Platelet-derived growth factor receptor a (PDGFRa) is specifically expressed by OPCs, which can differentiate into myelinating oligodendrocytes (49) . PDGFRa + cells were isolated from CD-1 wild-type mice between postnatal days 3 and 5 with the magnetic-activated cell sorting method (all devices and reagents purchased from Miltenyi Biotec, Bergisch-Gladbach, Germany; prepared according to the manufacturer's manual protocols) (50) . All institutional regulations regarding animal ethics were followed. Animals from both sexes were used, and cells were pooled regardless of their sex. The purity of the isolated PDGFRa + cells was assessed by fluorescence-activated cell sorting (FACS) analysis and was 92.22% 62.34% (mean 6 standard deviation). The isolated cells were seeded on 0.05% poly-DL-ornithine-coated (Sigma-Aldrich, Steinheim, Germany) wells in MACS NeuroMedium supplemented with 2% MACS NeuroBrew (both Miltenyi Biotec), 0.5 mM GlutaMAX, 1% penicillin-streptomycin (10,000 U/mL) (both Life Technologies, Thermo Fisher, Schwerte, Germany), 10 ng/mL fibroblast growth factor, and 10 ng/mL platelet-derived growth factor (both PeproTech, Hamburg, Germany). The same medium was used for experiments.
The rat-derived oligodendrocyte progenitor cell line OLN-93 [O4 + MBP 2 ; Research Resource Identifier (RRID): CVCL_5850] (51), a kind gift from Prof. Dr. Christiane Richter-Landsberg (University of Oldenburg, Germany), was cultured as described previously by Gerstner et al. (52) . The sex of OLN-93 cells was not reported previously but was determined by polymerase chain reaction (PCR). For experiments, medium was exchanged to Dulbecco's modified Eagle medium (Life Technologies) supplemented with 10% heat-inactivated fetal bovine serum, 1% penicillin-streptomycin, and 100 mM DL-buthionine-(S,R)-sulfoximine (BSO; Sigma-Aldrich). The BSO was used to suppress cellular resistance to oxidative stress by inhibiting g-glutamylcysteine synthetase, a key enzyme in glutathione biosynthesis (53) . Thus, BSO leads to a reduced antioxidant capacity as found in preterm infants (54) .
The rat-derived immature astroglial cell line C6 (S100b + GFAP 2 ; RRID:CVCL_0194) (55, 56) is genetically male and was purchased from the American Type Culture Collection (LGC Standards, Wesel, Germany). The cells were cultured in F-12K medium (Life Technologies) supplemented with 15% heat-inactivated horse serum (Biochrom, Merck, Darmstadt, Germany), 2.5% fetal bovine serum, and 1% penicillinstreptomycin. For experiments, medium was exchanged to Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin. All cells were cultured in a humidified atmosphere at 37°C and 5% CO 2 (21% O 2 , normoxia) (Binder, Tuttlingen, Germany). Neither cell line was used after 10 passages, and both were recently verified by a commercial service (DSMZ, Braunschweig, Germany).
PCR for sex determination
For sex determination, genomic DNA was extracted by using the QIAamp DNA isolation kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Rat sexdetermining region Y (SRY) gene PCR was performed by using the following SRY primers, as previously described by Ise et 27 M in DMSO, Sigma-Aldrich). The DMSO was added to the control sample corresponding to the DMSO concentration in the treatment sample.
After recovery overnight, PDGFRa + cells were pretreated for 12 hours with each compound as indicated. Afterward, cells were exposed to 12 hours of hyperoxia (humidified atmosphere at 37°C with 5% CO 2 and 80% O 2 ) (Binder).
After 48 hours of recovery in culture medium, OLN-93 and C6 media were exchanged to experimental media containing steroids, agonists, antagonists, aromatase inhibitor, or DMSO. After 2 hours of preincubation, the medium was renewed, and the cells were exposed to hyperoxia for the indicated time.
Cell survival assessment
FACS
Apoptotic cells were detected by using a caspase-3/7 assay kit (Life Technologies) according to the manufacturer's protocol. The detection reagent is nonfluorescent as the four-amino acid peptide DEVD inhibits the ability of the dye to bind to DNA. After activation of caspase-3/7 in apoptotic cells, the DEVD peptide is cleaved, enabling the dye to bind to the DNA and produce fluorescence. Additionally, the kit contains Sytox to stain for dead cells. Immediately after the staining, cells were measured by using BD LSR II (BD Bioscience, Heidelberg, Germany). The fluorescence emission of the detection reagent is approximately 533 nm; it is approximately 647 nm for Sytox. Results were assessed using FlowJo software (FlowJo, Ashland, OR). The viability of C6 cells was assessed with a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Promega, Mannheim, Germany) according to the manufacturer's instructions. In this assay, MTT, a yellow tetrazole, is reduced to purple formazan in living cells, and the conversion is measured by a plate reader at OD 595 nm. The OD 650 nm was measured as reference and subtracted from OD 595 nm. For better comparability among the survival assays, the results of the viability were processed to cell death for most experiments by the following formula: % cell death = 100 2 (% viability 2 100). Results are given as percentage cell death compared with DMSO-treated cells under hyperoxia.
Survival assays
Fluorescence
To stain for apoptosis, medium was exchanged to Annexin V-binding buffer (BioLegend, Fell, Germany) containing 1 mg/mL Hoechst 33342 (Sigma-Aldrich), 25 mL/mL Annexin V Alexa Fluor conjugate (BioLegend), and 12.5 mg/mL propidium iodide (Sigma-Aldrich). After 15 minutes incubation at 37°C, fluorescence was visualized by using a fluorescence microscope (DMI 4000b, Leica, Wetzlar, Germany). 
Western blotting
Proteins were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membranes (Bio-Rad Laboratories, Munich, Germany) in a wet transfer system (all devices purchased from Bio-Rad Laboratories). The membranes were blocked for 2 hours in Tris-buffered saline (Carl Roth, Karlsruhe, Germany) containing 0.15% Tween 20 (Sigma-Aldrich) and 2.5% nonfat milk (Carl Roth). Afterward, membranes were incubated overnight with primary antibodies and the next day for 1 hour with horseradish peroxidase-conjugated secondary antibodies. The following primary antibodies were used: anti-ER-a rabbit polyclonal antibody ( Peroxidase-conjugated goat anti-rabbit and goat anti-mouse IgG (H+L) secondary antibodies were purchased from Jackson ImmunoResearch (Table 1) . For positive controls, rat brain lysate, MCF-7, and NIH/3T3 whole cell lysates were used (all Santa Cruz). Specific proteins were visualized with enhanced chemiluminescence detection reagent according to the manufacturer's instructions (Thermo Fisher) and developed by an imaging system (ChemiDoc XRS, Bio-Rad Laboratories).
Statistical analysis
Statistical significance was assessed with GraphPad Prism 5 software (GraphPad, La Jolla, CA) by one-way analysis of variance followed by the Tukey post hoc test for multiple groups or Student t test for comparison of two data sets. In the figures, levels of significance were denoted as * (#,1) P , 0.05, ** (##,11) P , 0.01, and *** (###,111) P , 0.001. P , 0.05 was considered to indicate a statistically significant difference. Data in the figures are represented as mean 6 standard error of the mean (SEM) and are the results of at least four independent experiments performed on different days. When replicate wells were used, data were pooled (n = 1).
Results
Characteristics of investigated cells
Mice-derived primary PDGFRa + OPCs, the ratderived immature oligodendroglial cell line OLN-93, and the rat-derived immature astroglial cell line C6 were investigated. For all cell types, Western blot analysis was performed to detect ER-a, ER-b, GPER, and AR. PDGFRa + , OLN-93, and C6 cells expressed all receptors, but there was only a weak band of full-length ER-a in all cell types [Supplemental Fig. 1(a-d) ].
To verify the cell type, OLN-93 and C6 cells were stained for their phenotypic markers. Thus, C6 cells were stained for the astrocyte marker S100b and OLN-93 cells, for the oligodendrocyte marker O4 [Supplemental Fig. 2(a) and 2(b) ]. Furthermore, OLN-93 cells were induced into a more immature phenotype with a bipolar structure by a 6-day treatment with 10 ng/mL platelet-derived growth factor and 10 ng/mL fibroblast growth factor [Supplemental Fig. 2(c) ], as well as into a more mature phenotype with intense arborization by a 6-day treatment with 10 ng/mL ciliary neurotrophic factor, 5 mM forskolin, and 15 nM 3, 
Hyperoxia induces apoptotic cell death
The effect of hyperoxia (80% O 2 ) and BSO on OLN-93 cells was investigated by FACS analysis of the cell death marker Sytox [Supplemental Fig. 3(a) ]. Hyperoxia or BSO alone did not influence survival, and only the combination of both significantly increased cell death [F (3, 22) 
Protective effect of E2 is dose dependent
To investigate whether E2 protects against hyperoxiamediated cell death, PDGFRa + cells were pretreated for 12 hours with different concentrations of E2 or DMSO and afterward exposed to hyperoxia for 12 hours, as previously described by Gerstner et al. (58) . The survival assay revealed a dose-dependent protective effect with a median effective concentration (EC 50 ) of 1.14 3 10 After hyperoxia, E2-and DMSO-pretreated PDGFRa + cells were stained with Hoechst to identify viable cells, with Annexin V as an apoptosis marker, and with propidium iodide as dead cell stain. As shown in Fig 1(f) , E2-pretreated PDGFRa + cells displayed fewer apoptotic and dead cells compared with DMSO-treated cells.
Classical and nonclassical ERs can mediate protection
To investigate the receptors participating in E2-mediated protection, the ERa/ERb antagonist and GPER agonist ICI, GPER agonist G1, and GPER antagonist G36 were used. After treatment as described before, the rate of cell death was determined by using survival assays.
In PDGFRa + cells, none of these compounds alone influenced hyperoxia-mediated cell death, but when ICI was added to E2-treated cells, the protective effect of E2 was significantly blocked [ Fig. 2(a) ]. The G36 did not block E2-mediated protection, and a combination of both antagonists revealed no further protection that was mediated apart from receptors. A non-receptor-mediated mechanism was considered because of E2's structure, which could act as a radical scavenger (59) . The protective effects of E2 in PDGFRa + cells were therefore mediated via the classical ERs ER-a and/ or ER-b [F (7, 41) = 8.753; P , 0.0001]. In C6 cells, treatment with ICI and G1 alone led to significant protection that accounted for GPER-mediated protection [ Fig. 2(b) ]. When cells were cotreated with E2 and ICI or G36, respectively, the protective effect was significantly blocked. The cotreatment with both antagonists reduced the effects to the level of untreated cells, suggesting no further routes beyond the receptors. The protective effect of E2 in C6 cells was therefore mediated via classical ERs and the nonclassical ER GPER [F (7, 52) = 7.266; P , 0.0001].
In OLN-93 cells, ICI alone led to extensive cell death, whereas G36 alone led to significant cell survival under hyperoxia; neither treatment affected survival under normoxic conditions [ Fig. 2(c) ]. Induction of cell death after ICI treatment suggests that growth and survival in OLN-93 cells depended on classical ER signaling, similar to what commonly occurs in cancer cells (60) . This strong response to the antagonists did not allow investigation of cotreatment with E2, but only the classical ERs possessed the potential for mediating survival [F (8, 52) = 99.83; P , 0.0001].
Dose-dependent protective effect of fetal zone steroids
The fetal zone steroids DHEA, 16OH-DHEA, and Adiol were investigated under the same conditions as E2 in PDGFRa + , OLN-93, and C6 cells using survival assays. There was a dose-dependent protective effect of all tested fetal zone steroids in every investigated cell type [ Fig. 3(a-i) ]. Although dose-response curves were sigmoidal for PDGFRa + and OLN-93 cells, fetal zone steroids displayed U-shaped dose-response curves in C6 cells. Table 2 shows a summary of the EC 50 of each fetal zone steroid and E2 in each cell type.
Receptors involved in DHEA-mediated protection The next step was to investigate the receptors participating in fetal zone steroid-mediated protection. With DHEA used as a representative, the ER antagonists ICI and G36 and the AR antagonist CDX were applied in survival assays.
In PDGFRa + cells, CDX alone significantly reduced hyperoxia-mediated cell death, which accounted for cell death signaling via the AR [ Fig. 4(a) + cells were pretreated for 12 hours with different concentrations of E2 or DMSO followed by hyperoxia for 12 hours. Applied concentrations as labeled in the graphs. Afterward, the rate of cell death was determined by survival assays. After 2 hours of pretreatment with E2 or DMSO and 48 hours of hyperoxia, the rate of cell death of (b) C6 and (c) OLN-93 cells was determined by survival assays. Values are expressed as means 6 SEM. Significant differences from controls (DMSO) are indicated by *P , 0.05, **P , 0.001, and ***P , 0.0001. Caspase-3/7 activation upon E2 pretreatment compared with DMSO in (d) C6 and (e) OLN-93 cells was analyzed by FACS. Values are expressed as means 6 SEM. Significant differences from hyperoxia with DMSO are indicated by *P , 0.05. Black bars represent hyperoxia. (f) PDGFRa + cells were pretreated for 12 hours with 100 nM E2 or DMSO followed by hyperoxia for 12 hours. Afterward, cells were stained with Hoechst to visualize viable cells, with Annexin V as an apoptosis marker and propidium iodide as a dead-cell stain. Scale bar = 100 mm.
In C6 cells, CDX alone did not influence hyperoxiamediated cell death [ Fig. 4(b) ]. Cotreatment of DHEA with ICI as well as CDX led to a significant reduction in the DHEA-mediated protection, whereas cotreatment with G36 did not influence the protective effect of DHEA. The cotreatment with all antagonists reduced the effects to the level of untreated cells, suggesting no further routes beside these receptors. The protective effect of DHEA in C6 cells was therefore mediated via classical ERs and the AR [F (9,78) = 6.456; P , 0.0001].
In OLN-93 cells, CDX alone led to extensive cell death, just like ICI under hyperoxia, whereas these treatments did not affect survival under normoxic conditions [ Fig. 4(c) ]. These results suggest that the classical ERs and AR mediate survival signaling in OLN-93 cells and that these cells could therefore depend on both estrogen and androgen signaling. Because of the apoptosisinducing effect of CDX, it was not possible to clarify the receptors involved in the DHEA-mediated protection in OLN-93 cells, but classical ERs and AR both possessed the potential [F (5, 36) = 96.10; P , 0.0001]. Table 3 shows a summary of the receptors that most likely mediate the protective effects of E2 and DHEA in the investigated cell types.
Intracellular aromatases can influence protection
The CYP19 aromatase inhibitor Exe was applied in survival assays to investigate whether intracellular conversion of fetal zone steroids into more estrogenic compounds occurs and how such conversion might affect the protective properties of fetal zone steroids.
Neither Exe alone nor cotreatment of fetal zone steroids with Exe altered the fetal zone steroid-mediated protection in PDGFRa + cells [F (7,27) = 14.64; P , 0.0001] [ Fig. 5(a) ].
In C6 cells, Exe alone did not influence hyperoxia-mediated cell death [ Fig. 5(b) ]. Cotreatment of fetal zone steroids with Exe led to reduced protective properties of the fetal zone steroids, which was significant in the case of 16OH-DHEA. Therefore, CYP19 aromatase activity in C6 cells converted fetal zone steroids into more estrogenic compounds that induced a more powerful protective effect than unconverted fetal zone steroids [F (9,79) = 9.839; P , 0.0001].
In OLN-93 cells, Exe alone did not influence hyperoxia-mediated cell death [ Fig. 5(c) ]. Cotreatment of fetal zone steroids with Exe led to increased protective effects, which were not significant. This result suggests CYP19 aromatase activity in OLN-93 cells that converts fetal zone steroids, but unconverted fetal zone steroids tended to be more protective [F (9,108) = 16.46; P , 0.0001].
Western blot analysis showed CYP19 expression in C6 and OLN-93 cells but not in PDGFRa + cells [ Fig. 5(d) ].
Synergistic effects in OLN-93 cells but not in C6 and PDGFRa + cells To investigate the effect of cotreatment on hyperoxiamediated cell death, treatment with fetal zone steroids alone was compared with cotreatment with E2 using survival assays and FACS analysis of caspase-3/7 activation. To determine the role of ERs in mediating protection, the ER-a and ER-b antagonist and GPER agonist ICI, GPER agonist G1, and GPER antagonist G36 were used. Applied concentrations as labeled in the graphs. After treatments as described previously, the rate of cell death was measured in (a) PDGFRa + cells and (b) C6 cells. Values are expressed as means 6 SEM. Significant differences from hyperoxia with DMSO are indicated by *P , 0.05, **P , 0.001, and ***P , 0.0001; significant differences from E2-treated cells (hyperoxia with E2) are indicated by #P , 0.05, ##P , 0.001, and ###P , 0.0001. (c) In OLN-93 cells, the results of the survival assays were normalized to normoxia. Values are expressed as means 6 SEM. Here, significant differences from normoxia with DMSO are indicated by *P , 0.05, **P , 0.001, and ***P , 0.0001; significant differences from hyperoxia with DMSO are indicated by #P , 0.05, ##P , 0.001, and ###P , 0.0001. Significant differences with treatment between normoxia and hyperoxia are indicated by +++P , 0.0001. White bars represent normoxia, and black bars represent hyperoxia.
In PDGFRa + cells, the protective effect of cotreatment with E2 was not improved compared with treatment with fetal zone steroids alone [F (7, 49) = 8.373; P , 0.0001] [ Fig. 6(a) ].
Also in C6 cells, cotreatment with E2 was not superior to fetal zone steroid single treatment in survival assays [F (7, 51) In OLN-93 cells, on the other hand, the protective effect of the cotreatment was significantly enhanced 
Discussion
During pregnancy, fetal zone steroids are synthesized by the fetus and serve as precursors for estrogen synthesis in the placenta (21) . We and others have previously shown that fetal zone steroid synthesis in preterm born infants is persistently high until term (25, 26) . Our recent review of the related literature suggested that fetal zone steroids can activate classical ERs, which could lead to protective properties against apoptotic cell death (20). This potential might explain suppressed effects on the neurologic outcome of premature infants who were treated to maintain intrauterine E2 and progesterone concentrations (31) . Furthermore, the current experimental models for prematurity are questioned owing to the presence of huge quantities of fetal zone steroids that are not taken into account. In this study, fetal zone steroid treatment resulted in significant dose-dependent protection against hyperoxia-induced cell death in three different immature glial cell types. The effects were comparable to those of E2. However, no synergism in fetal zone steroid and E2 cotreatment was detected in two of the three cell types.
Mechanisms of E2-mediated protection
In any tested cell types, E2 treatment resulted in a significant dosedependent protection, whereas the mediating receptors differed. In primary OPCs and the immature oligodendroglial cell line OLN-93, it was previously shown that E2 protects against hyperoxia-induced apoptosis by preventing proapoptotic caspase-3 activation (12, 61) . The protectionmediating receptors were not further investigated in those studies. In case of 3-(4-morpholinyl)-sydnonimine-induced cell death, classical ERs were associated with the protective effects of E2 in OPCs (62), which was also the case in our experiments with PDGFRa + OPCs and OLN-93 cells. Sur et al. (32) showed that E2 attenuates oxidative stress-induced apoptosis in the immature astroglial cell line C6 by reducing caspase-3 activation, which was confirmed in our experiments. Furthermore, in a model of glutamate-induced apoptosis in C6 cells, E2 was protective via a receptor-mediated mechanism (63) . In that study, the authors found a significant reduction in E2's protective effect when ICI was added and concluded that classical ERs mediate the protection. Interestingly, they also found significant protection when glutamate-treated Figure 4 . Receptors involved in DHEA-mediated protection. To determine the receptors involved in DHEA-mediated protection, ICI, G36, and the AR antagonist bicalutamide (CDX) were used. Applied concentrations as labeled in the graphs. After treatments as described previously, the rate of cell death was measured in (a) PDGFRa + cells and (b) C6 cells. Values are expressed as means 6 SEM. Significant differences from hyperoxia with DMSO are indicated by **P , 0.001 and ***P , 0.0001; significant differences from DHEA-treated cells (hyperoxia with DHEA) are indicated by #P , 0.05, ##P , 0.001, and ###P , 0.0001. (c) In OLN-93 cells, the results of the survival assays were normalized to normoxia. Values are expressed as means 6 SEM. Significant differences from normoxia with DMSO are indicated by ***P , 0.0001; a significant difference from hyperoxia with DMSO is indicated by ###P , 0.0001; and a significant difference with treatment between normoxia and hyperoxia is indicated by +++P , 0.0001. White bars represent normoxia; black bars represent hyperoxia. cells were incubated with ICI alone. This result was not further discussed in the paper, but ICI can also act as an agonist for GPER. Our results reflect the same finding in hyperoxia-induced cell death in C6 cells, according to which classical and nonclassical ERs can mediate E2's protection. Furthermore, our experiments revealed no further protection that was mediated apart from receptors despite of E2's structure, which could serve as a radical scavenger (59) .
Fetal zone steroids are protective against hyperoxia-induced cell death and show similarities with E2-mediated mechanisms
In all investigated cell types, DHEA, 16OH-DHEA, and Adiol treatment resulted in a significant dose-dependent protection comparable to our findings in E2 treatment. In case of DHEA, the effect was mediated via classical ERs, whereas the AR could support survival and cell death depending on the cell type.
To our knowledge, no literature has addressed fetal zone steroid-mediated antiapoptotic effects in OPCs or OLN-93 cells. Caruso et al. (64) found that exposure of OPCs to testosterone induced a slight toxicity that was mediated by the AR. Accordingly, after blocking the AR in PDGFRa + cells, we found a significant decrease in cell death. In contrast, after blocking the AR in OLN-93 cells, we found a significant induction of cell death under hyperoxia. This seemingly contradictory action of the AR is well known and depends on the cell type and the microenvironment (65, 66) . In our study, classical ERs mediated the protective effect of DHEA in PDGFRa + OPCs, whereas classical ERs and AR possessed the potential to mediate protection in OLN-93 cells.
In a model of immunostimulated and glucose-deprived C6 cells, DHEA inhibited cell death in a dose-dependent manner (67) . From 10 to 100 mM DHEA, increasing protection was detected in those experiments. In contrast to these results, we identified a maximum protection of DHEA at approximately 100 nM that had already disappeared at 1 mM. This difference might be explained by To determine the effect of cotreatment on hyperoxia-mediated cell death, treatment with E2 alone and fetal zone steroid single treatment was compared with cotreatment. Applied concentrations as labeled in the graphs. After treatments as described before, the rate of cell death was measured in (a) PDGFRa + cells and (b) C6 cells. Values are expressed as means 6 SEM. Significant differences from hyperoxia with DMSO are indicated by **P , 0.001 and ***P , 0.0001. To verify the effect of cotreatment on hyperoxia-mediated cell death, caspase-3/7 activation in (c) C6 cells was measured by FACS. Values are expressed as means 6 SEM. Significant differences from normoxia with DMSO are indicated by ***P , 0.0001; significant differences from hyperoxia with DMSO are indicated by #P , 0.05 and ##P , 0.001. White bars represent normoxia, and black bars represent hyperoxia. After treatments as described before, the rate of cell death was measured in (d) OLN-93 cells. Values are expressed as means 6 SEM. Significant differences from hyperoxia with DMSO are indicated by **P , 0.001 and ***P , 0.0001; significant differences from fetal zone steroid-treated cells compared with fetal zone steroid/E2 cotreated cells are indicated by ###P , 0.0001. To verify the effect of cotreatment on hyperoxia-mediated cell death, caspase-3/ 7 activation in (e) OLN-93 cells was measured by FACS. Values are expressed as means 6 SEM. Significant differences from normoxia with DMSO are indicated by **P , 0.001 and ***P , 0.0001; significant differences from hyperoxia with DMSO are indicated by #P , 0.05, ## , 0.001, and ###P , 0.0001. White bars represent normoxia, and black bars represent hyperoxia.
Intracellular aromatases influence the protective properties of fetal zone steroids
The CYP19 aromatase causes the intracellular conversion of fetal zone steroids into more estrogenic compounds that interact more strongly with the ERs. The CYP19 aromatase is mainly expressed in neurons but can be induced in astrocytes after brain injury (68) . In C6 cells, CYP19 activity has been previously described (69) , and we found a protection-supporting effect of the aromatase in fetal zone steroid-mediated protection in these cells. In OLN-93 cells, we identified CYP19 aromatase activity, which is frequently observed in estrogendependent cancer cells (70) . Here, inhibition of the aromatase activity led to a nonsignificant increase in the fetal zone steroid-mediated protection, which suggests that the AR acts as a strong mediator in antiapoptotic signaling by fetal zone steroids. Primary OPCs were previously found to be aromatase negative (71) . Accordingly, we could not detect any effect on aromatase inhibition in PDGFRa + primary cells.
No synergism in protection in two of the three investigated cell types In C6 and PDGFRa + cells, we observed no synergistic effects of cotreatment compared with E2 and fetal zone steroid single treatment, which supported our initial hypothesis. In contrast, however, OLN-93 cells revealed synergistic effects in the cotreatment group. https://academic.oup.com/endoTherefore, it is not possible to develop a single general conclusion. Figure 7 shows the variety of options that evolved from our findings: If classical ERs are mediating the protective effects of fetal zone steroids, their intracellular conversion into more estrogenic compounds by aromatases leads to a more powerful activation of the receptor-mediated effects, as in the C6 cells [ Fig. 7(a) and 7(b) ]. Nevertheless, if the maximal activity of the receptor-mediated processes is achieved, there is no further benefit by adding more substances that will take the same route (e.g., E2). In this case, no synergistic effects will be achieved with cotreatment. On the other hand, the intracellular conversion of fetal zone steroids could be helpful in preventing unwanted signaling, such as proapoptotic actions of AR [ Fig. 7(c) ]. In the case of classical ERs and AR mediating the protective effects, there are two options: One receptor is more powerful in mediating the effect or both receptors are equal in generating a protective response. Even if DHEA can mediate protection via classical ERs and AR in C6 cells, the classical ERs seem to mediate the larger proportion of protection [ Fig. 7(d) ]. This predominant mediation via the ERs might be explained by or is only intensified by the aromatase activity that gives rise to more ER-interacting compounds. However, the dominant route of action via classical ERs seems to lead to a maximum effect that cannot be significantly enhanced any more by cotreatment with E2 [ Fig. 7(e) ]. In the case of OLN-93 cells, the classical ERs and AR seem to possess the same potential in mediating the protective effects [ Fig. 7(f) ]. Inhibition of aromatase activity leads to increased protection of fetal zone steroids, underpinning the strong protective potential of the AR. The synergistic effect of cotreatment suggests that E2 activates classical ERs, whereas fetal zone steroids activate AR. Whether the fetal zone steroids themselves act on AR or are processed by 3b-and 17b-hydroxysteroid dehydrogenases to more potent androgens remains to be clarified. Nevertheless, without competition for the same receptor, cotreatment can lead to synergistic effects [ Fig. 7(g) ].
Strength and limitations
The strength of our study is the use of three different immature glial cell types (i.e., immature primary cells from neonatal rodents and cell lines of immature cell subpopulations) to explore cell type-specific outcomes. The neuroprotective effects of the fetal zone steroids were shown to highly depend on the cell type-specific expression of aromatases, the receptor repertoire, and the potency of the fetal zone steroids toward these receptors. Thus, the three investigated cell types resulted in three different explanations of how the mechanism of protection works and why synergism does (not) occur. Nevertheless, the synergistic effects as shown in OLN-93 cells are not likely to occur in preterm infants because of the receptor affinities of the human receptors that will not lead to predominant AR activation by fetal zone steroids (e.g., DHEA: ER-b K d ; 0.5 mM; AR K d ; 1.1 mM) (47, 72) .
The goal of this study was to investigate fetal zone steroids under the same conditions as E2-mediated protection. However, some general aspects (e.g., hormone concentrations and incubation times) could have influenced the results. The longer the preincubation with the steroids, the more genomic effects that might have resulted in an altered outcome could have been induced. Furthermore, we have combined concentrations that showed significant protection in the dose-response curves. Lower concentrations of E2 and fetal zone steroids could have acted synergistically at classical ERs in all cell types. In case of the U-shaped dose-response curves of the fetal zone steroids in C6 cells, the addition of E2 could have led to a shift of the maximum, which merits further investigation.
By using selective estrogen receptor modulators that are selective antagonists to ER-a or ER-b, it would be possible to distinct between ER-a and ER-b-mediated effects in future experiments. Finally, primary OPCs proliferation and maturation are differentially regulated by male and female sex steroids, and there are differences between female-derived immature oligodendrocytes and their male-derived counterparts (73, 74) . In our case, the PDGFRa + cells were a mixed population from both sexes.
However, future experiments with cells derived from males and females separately could possibly give better insights into the precise role of the sex-related aspects.
Clinical relevance
In a large cohort of more than 900 extremely low birth weight (,1000 g) infants, a simple count of three common neonatal morbidities strongly predicted the risk for later death or neurosensory impairment (75) . The key pathogenic factor of these three morbidities is hyperoxia. The therapeutic application of E2 has been tested in these three morbidities as a therapeutic measure: in experimental settings of (a) retinopathy of prematurity (76) , (b) bronchopulmonary dysplasia (77) , and (c) morbidities of the central nervous system, as discussed here. Hence, protective strategies are needed in different pediatric diseases in which sex steroids may play an important role.
Conclusion
Previous in vitro and in vivo experimental approaches focused solely on the immaturity of the brain. The investigated fetal zone steroids DHEA, 16OH-DHEA, and Adiol activate ER-a and/or ER-b as well as AR. Here, we have shown that this interaction is strong enough to mediate protection in a model of hyperoxia-mediated cell death in immature glial cells. These estrogen precursors circulate in persistently high concentrations in preterm infants, so we expect continuous activation of both classical ERs in the preterm infant despite the lack of placental estrogen supply. This continuous activation might lead to a kind of per se transient endogenous neuroprotection and support of the premature infant's regular development. Furthermore, cotreatment with E2 in the presence of fetal zone steroids does not add up to the fetal zone steroid-initiated processes, probably because E2 and fetal zone steroids compete for binding the classical ERs, which will end in saturation. This unique hormonal milieu of a preterm infant might be the reason that no potent neuroprotective effect was found in previous preliminary clinical studies of E2 and progesterone supplementation. The concept of involving fetal zone steroids in an immature model system should be considered in future studies for potential treatments in any disease of the preterm infant.
